This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sabatino, D. E.
Right arrow Articles by Bodine, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabatino, D. E.
Right arrow Articles by Bodine, D. M.

 Previous Article  |  Next Article 

Molecular and Cellular Biology, November 1998, p. 6634-6640, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.

Substitution of the Human beta -Spectrin Promoter for the Human Agamma -Globin Promoter Prevents Silencing of a Linked Human beta -Globin Gene in Transgenic Mice

Denise E. Sabatino,1 Amanda P. Cline,1 Patrick G. Gallagher,2 Lisa J. Garrett,1 George Stamatoyannopoulos,3 Bernard G. Forget,2 and David M. Bodine1,*

Hematopoiesis Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Bethesda, Maryland1; Yale University, New Haven, Connecticut2; and University of Washington, Seattle, Washington3

Received 18 May 1998/Returned for modification 6 July 1998/Accepted 23 July 1998

    ABSTRACT
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

During development, changes occur in both the sites of erythropoiesis and the globin genes expressed at each developmental stage. Previous work has shown that high-level expression of human beta -like globin genes in transgenic mice requires the presence of the locus control region (LCR). Models of hemoglobin switching propose that the LCR and/or stage-specific elements interact with globin gene sequences to activate specific genes in erythroid cells. To test these models, we generated transgenic mice which contain the human Agamma -globin gene linked to a 576-bp fragment containing the human beta -spectrin promoter. In these mice, the beta -spectrin Agamma -globin (beta sp/Agamma ) transgene was expressed at high levels in erythroid cells throughout development. Transgenic mice containing a 40-kb cosmid construct with the micro-LCR, beta sp/Agamma -, psi beta -, delta -, and beta -globin genes showed no developmental switching and expressed both human gamma - and beta -globin mRNAs in erythroid cells throughout development. Mice containing control cosmids with the Agamma -globin gene promoter showed developmental switching and expressed Agamma -globin mRNA in yolk sac and fetal liver erythroid cells and beta -globin mRNA in fetal liver and adult erythroid cells. Our results suggest that replacement of the gamma -globin promoter with the beta -spectrin promoter allows the expression of the beta -globin gene. We conclude that the gamma -globin promoter is necessary and sufficient to suppress the expression of the beta -globin gene in yolk sac erythroid cells.

    INTRODUCTION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Hemoglobin switching describes the changes that occur in the sites of erythropoiesis during development as well as the changes in the globin genes that are expressed (51). The human beta -like globin genes (5'varepsilon Ggamma Agamma delta beta 3') are located in an ~75-kb region on the short arm of chromosome 11 and are arranged 5' to 3' in the order in which they are expressed during development (9, 58). The earliest human erythroid cells express varepsilon -globin and are derived from the embryonic yolk sac. At 16 weeks of gestation, the fetal liver is the site of erythropoiesis. Fetal liver-derived erythroid cells express the duplicated gamma -globin genes, while the varepsilon -globin gene is silenced (45). By birth, the major site of erythropoiesis is the bone marrow, which expresses the delta - and beta -globin genes only (for reviews, see references 9, 23, 31, 51, and 58).

The locus control region (LCR), a group of DNase I-hypersensitive sites located upstream of the globin cluster, is the most important cis-regulatory element for the beta -like globin cluster (14, 19). Many studies have shown that the LCR is essential for high-level expression of globin genes in transgenic mice (15, 19, 47). In the absence of the LCR, individual human beta -like globin genes are expressed in transgenic mice at low levels but in a developmentally appropriate manner (7, 26, 29, 52, 53).

The effects of the LCR on the developmental stage-specific expression of the human beta -like globin genes are complex. In transgenic mice with the LCR and a single human gamma - or beta -globin gene, no developmental stage-specific expression has been observed (23, 31). The globin genes are expressed in yolk sac, fetal liver, and adult erythroid cells. However, when the LCR was linked to both a gamma - and a beta -globin gene, the developmental changes in gene expression were restored; the gamma -globin genes were expressed in yolk sac- and fetal liver-derived erythroid cells, and the beta -globin genes were expressed in fetal liver and adult erythroid cells (4, 12). Other studies made use of marked beta -globin genes whose mRNAs could be distinguished from those of unmarked beta -globin genes. Marked beta -globin genes were inserted at different positions within a beta -globin locus cosmid. These studies showed that both the position of the marked beta -globin gene and the distance between the LCR and the genes in the cosmid construct determined the levels of both the marked and unmarked beta -globin mRNAs (10, 39).

These and other studies of hemoglobin switching have suggested several models for the developmental regulation of the beta -like globin genes which are not mutually exclusive. One model suggests that the gene order and distance of a gene from the LCR (polarity) determine the correct developmental expression pattern (20, 39). A second model proposes that the LCR serves only as an enhancer element, allowing high-level expression of the globin genes which are activated by developmental stage-specific elements (31). The competition model proposes that erythroid cells of each developmental stage contain stage-specific elements which compete for and stabilize interactions between globin genes and the LCR (8, 23).

All of these models suggest that elements near or within the individual globin genes are required for developmental activation and/or suppression of the beta -like globin locus. Physical evidence for interactions between the LCR and individual globin genes has been shown by in situ hybridization analysis of erythroid cells from transgenic mice with a complete beta -globin locus. Analysis of individual nuclei labeled with LCR, gamma -globin, and beta -globin probes have shown that the LCR interacts with only "one gene at a time" (56).

Other studies have shown that transgenic mice containing an LCR, a gamma -globin gene with a promoter deletion, and the beta -globin gene do not express the gamma -globin gene at any stage of development, while the beta -globin gene is expressed throughout development (3). Similarly, transient transfection studies of K562 cells have demonstrated that deletion of the proximal gamma -globin promoter allows expression from a downstream beta -globin promoter (24, 25). Both groups concluded that the gamma -globin promoter sequences were responsible for the silencing of the downstream beta -globin gene, but they could not exclude the possibility that gamma -globin gene expression prevented beta -globin gene expression in embryonic erythroid cells.

One prediction of the competition model for hemoglobin switching is that a heterologous promoter attached to a gamma -globin gene would not compete for stage-specific elements or the LCR and would therefore permit the expression of a downstream beta -globin gene in embryonic erythroid cells. To test this hypothesis, we fused a 576-bp fragment of the human beta -spectrin promoter characterized by Gallagher et al. (18) to a human gamma -globin gene and generated transgenic mice containing the beta -spectrin/Agamma -globin gene. We chose the promoter from the beta -spectrin gene because beta -spectrin is expressed at relatively high levels in erythroid tissues and does not exhibit changes in expression during development (44, 57).

Analysis of transgenic mice containing only beta -spectrin/Agamma -globin genes demonstrated that the human beta -spectrin promoter directed high levels of gamma -globin mRNA in the absence of the LCR at all stages of development. In transgenic mice in which the human beta -spectrin promoter was substituted for the human Agamma -globin promoter in a cosmid construct containing a micro-LCR (µLCR) and Agamma -, psi beta -, delta -, and beta -globin genes, both the beta -spectrin/Agamma -globin and beta -globin genes are expressed throughout development. We conclude from these data that sequences within the gamma -globin promoter, and not gamma -globin transcription or intragenic sequences, are necessary and sufficient to silence the downstream beta -globin gene.

(This work was performed by Denise E. Sabatino in partial fulfillment of the doctoral degree requirements in the Graduate Genetics Program of the Columbian School of Arts and Sciences at George Washington University.)

    MATERIALS AND METHODS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Plasmid and cosmid constructs. A 576-bp fragment containing the beta -spectrin promoter (beta sp) was excised from pGL2B (18) as a KpnI/HindIII fragment and cloned into the KpnI/HindIII sites of pSP72. The HindIII site in plasmid pSP72 beta sp was destroyed by digestion with HindIII, filling in the ends, and religation. A 1,909-bp BsaHI/HindIII fragment containing the coding region of the human Agamma -globin gene was cloned into the ClaI/HindIII sites of pSP72. A 2,614-bp AatII/PvuII fragment from the beta sp plasmid was ligated to a 2,266-bp EcoRV/AatII fragment from the Agamma -globin plasmid to create pSP72 beta sp/Agamma . The construct was confirmed by sequencing across the beta sp/Agamma exon 1 region. The 2,483-bp beta sp/Agamma gene was excised from this plasmid with EcoRV and HindIII for microinjection.

HS2 beta sp/Agamma was generated by a triple ligation using a 712-bp XhoI/HincII fragment containing hypersensitive site 2 (HS2) of the LCR (33, 50), a 2,483-bp EcoRV/HindIII fragment containing beta sp/Agamma , and the vector pBluescript II KS+ cut with XhoI and HindIII. The 3,182-bp HS2 beta sp/Agamma gene was excised from this plasmid with HindIII for microinjection.

The pBluescript II KS+ plasmid vector was modified by replacing the BstXI site in the polylinker with KpnI and Bsp120I sites to generate BS*. A 4,428-bp NotI/XhoI fragment of the µLCRAgamma psi beta delta beta cosmid (12) containing the µLCR and a portion of the Agamma gene was cloned into the NotI/XhoI sites of BS* to generate µLCR Agamma 5'. This plasmid was digested with NotI and BamHI (polylinker) to generate the 2,972-bp fragment 1 of a four-part ligation. Fragment 2 was a 2,552-bp NotI/HindIII fragment containing the µLCR gene sequences from µLCR Agamma 5'. Fragment 3 was a 964-bp HindIII/StuI fragment of µLCR Agamma 5' containing the sequences from -1345 to -381 upstream of the Agamma promoter. The KpnI site in the 5' polylinker of pSP72 beta sp/Agamma was destroyed by KpnI digestion, filling in the ends, and religation. Fragment 4 was a 1,042-bp EcoRV/BamHI fragment containing beta sp/Agamma gene sequences from this plasmid. The product of this ligation was designated µLCR beta sp/Agamma 5'. This plasmid was partially digested with Bsp120I and completely digested with HindIII to generate the 2,580-bp fragment 1 of a three-part ligation containing the µLCR. Plasmid µLCR beta sp/Agamma 5' was digested partially with XhoI and completely with HindIII to generate the 2,059-bp fragment 2 containing beta sp/Agamma and upstream sequences. The third fragment was a 35.2-kb NotI/XhoI fragment of the µLCRAgamma psi beta delta beta cosmid (12). The resulting ligation generated the µLCRbeta spAgamma psi beta delta beta cosmid. The 40-kb µLCRbeta spAgamma psi beta delta beta fragment was excised from this cosmid by digestion with KpnI for microinjection. The control µLCRAgamma psi beta delta beta fragment was excised from the µLCRAgamma psi beta delta beta cosmid by digestion with NotI and KpnI for microinjection as described previously (12).

Generation of transgenic mice. Transgenic mice were generated as described by Hogan et al. (21). Fertilized eggs were collected from superovulating FVB/N female mice approximately 9 h after mating to CB6 F1 male mice. Fragments for microinjection were separated on agarose gels and concentrated by using a DNA Geneclean isolation system according to the manufacturer's instructions. The fragments were diluted to a concentration of 1 µg/ml in 7.5 mM Tris-HCl-0.25 mM EDTA (pH 7.5), and 1 to 3 pl was injected into the male pronuclei of fertilized eggs. The injected eggs were transferred to pseudopregnant CB6 F1 foster mothers. Founder animals were identified by Southern blotting (30) of DNA extracted from tail biopsies. Southern blots were probed with human beta -spectrin and/or human beta -globin probes. Copy number was determined by comparing transgenic mouse DNA to K562 DNA on a Southern blot and analysis using a Molecular Dynamics PhosphorImager. Founder animals were crossed to FVB/N mice for propagation and developmental studies.

Cellulose acetate electrophoresis. Blood samples were collected from 10.5-day embryos, 13.5-day embryos, and adult mice. Samples were lysed in cystamine as described by Whitney (55). Samples were run at 300 V for 20 min in a Titan electrophoresis chamber (Helena Laboratories), stained with Ponceau S (in 5% trichloroacetic acid) for 10 min, and destained in 7% acetic acid for 10 min (twice). The gels were fixed in methanol for 5 min (twice), cleared in a solution of 15 ml of glacial acetic acid, 35 ml of methanol, and 2 ml of Clear Aid for 7.5 min, and dried at 50 to 60°C for 15 min. The globin chain composing each hemoglobin tetramer was confirmed by acid-urea gel electrophoresis (1) of hemoglobins separated by cellulose acetate electrophoresis.

RNase protection assays. Total cellular RNA was extracted from 10.5-day embryo blood cells, 13.5-day fetal livers, and adult reticulocytes, using TRIZOL reagent (Gibco BRL, Life Technologies, Inc., Grand Island, N.Y.). Linear DNA templates for the RNase protection assay were prepared by EcoRI (beta sp/Agamma ), HindIII (mouse alpha ), and HindIII (human beta ) digestion of cesium chloride-purified plasmid preparations. The templates were purified by agarose gel electrophoresis and purified by using a Geneclean II kit (Bio 101, Inc., Vista, Calif.). 32P-labeled RNA probes were transcribed by using a MAXIscript in vitro transcription kit (Ambion, Inc., Austin, Tex.). Hybridization of the probe and the RNA (1 µg) was carried out overnight according to the standard procedure for the RPA II RNase protection assay kit (Ambion). RNase digestion was performed with an RNase A-RNase T1 mixture in RNase digestion buffer (Ambion), and the protected fragments were separated on an 8% nondenaturing polyacrylamide gel (SEQUAGEL-8; National Diagnostics, Atlanta, Ga.).

Immunofluorescence analysis. Fetal liver cells from transgenic mice and control littermates were stained with two monoclonal antibodies. One antibody, directed against human gamma -globin, was directly conjugated to fluorescein isothiocyanate (FITC); the second monoclonal antibody, against human beta -globin, was directly conjugated to rhodamine. The same field of cells was photographed under different exposure conditions: with an FITC filter (for detection of gamma -globin), with a rhodamine filter (for detection of beta -globin), and with first an FITC filter and then a rhodamine filter for a double exposure.

    RESULTS
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Transgenic mice with human gamma -globin single-gene constructs. We created two single-gene constructs containing the beta -spectrin promoter fragment linked to the human Agamma -globin gene, beta sp/Agamma and HS2 beta sp/Agamma (6, 15, 27, 33, 42, 50, 54) (Fig. 1; see Materials and Methods). Three transgenic mouse lines and two 13.5-day fetal livers containing beta sp/Agamma were analyzed. RNase protection demonstrated that two of three beta sp/Agamma transgenic lines and one of two fetal livers expressed the beta sp/Agamma transgene in erythroid cells. No beta sp/Agamma mRNA was detected in erythroid cells of the third transgenic line and the other fetal liver. Analysis of RNA extracted from a variety of organs and tissues of adult beta sp/Agamma transgenic mice revealed high levels of beta sp/Agamma mRNA in reticulocytes, bone marrow, and spleen and lower levels in thymus and other tissues (Fig. 2) (18). Much of the globin mRNA in nonerythroid cells can be attributed to the high reticulocyte counts (~15%) associated with a mild thalassemia caused by the excess of beta -like globin chains in these and all other transgenic mouse lines described in this study (18).


View larger version (17K):
[in this window]
[in a new window]
 
FIG. 1.   beta -Spectrin/gamma -globin single-gene constructs used to generate transgenic mice. The beta -spectrin promoter fragment (576 bp) is fused to the Agamma coding sequence at position -3 (A). A 712-bp fragment containing HS2 of the LCR is linked to the beta -spectrin/gamma -globin gene (B). Transgenic mice were identified by Southern blot analysis using a 576-bp beta -spectrin promoter probe.


View larger version (35K):
[in this window]
[in a new window]
 
FIG. 2.   RNase protection analysis of beta sp/Agamma mRNA expression in transgenic mice. (A) RNase protection of 10 µg of K562 RNA and 1 µg of adult reticulocyte mRNA from strain beta sp/Agamma A. 32P-labeled 1,493-bp RNA containing beta sp/Agamma gene sequences from exon 2, intron 1, and the beta sp/Agamma exon 1 fusion region was used as a probe. The positions of 32P-labeled, protected RNA fragments corresponding to Agamma -globin exon 2, beta sp/Agamma exon 1, and Agamma -globin exon 1 are indicated. (B) RNase protection of 1 µg of bone marrow (BM) and spleen RNA and 10 µg of thymus RNA from strain beta sp/Agamma A. Labeled RNA fragments corresponding to the beta sp/Agamma (exon 2 shown), mouse alpha -globin (exon 2), and mouse actin (control) mRNAs were used as probes.

The number of transgenes in each line was estimated by Southern blot analysis to be between three and six copies per expressing animal (Table 1). The level of beta sp/Agamma mRNA was compared to the mRNA output of the four mouse alpha -globin genes. After correction for copy number, the mean beta sp/Agamma globin gene mRNA level in adult reticulocytes was approximately 32% of the level of the alpha -globin mRNA (Table 1).

                              
View this table:
[in this window]
[in a new window]
 
TABLE 1.   Expression of beta sp/Agamma mRNA in transgenic mouse lines

Six transgenic lines and one 13.5-day fetal liver containing HS2 beta sp/Agamma were analyzed. Expression of beta sp/Agamma was detected in erythroid cells of all six lines and the fetal liver. Southern blot analysis revealed a copy number of 0.5 to 3 copies per animal. Two animals with less than one copy per cell did not transmit transgenes to F1 progeny and were determined to be mosaic for the transgene. After correction for copy number, the mean level of beta sp/Agamma mRNA in adult reticulocytes was 47% of the level of alpha -globin mRNA (Table 1). This difference was not statistically different from the levels observed in beta sp/Agamma transgenic mice.

RNA was extracted from 10.5-day-postcoitum (dpc) yolk sac derived peripheral blood cells, 13.5-dpc fetal livers, and adult reticulocytes for RNase protection analysis of beta sp/Agamma mRNA levels during development. In all transgenic lines expressing either beta sp/Agamma or HS2 beta sp/Agamma , the gamma -globin gene was expressed at all developmental stages at levels ranging from 4 to 37% of the levels of mouse alpha -globin expression in the same cells (Fig. 3; Table 1).


View larger version (45K):
[in this window]
[in a new window]
 
FIG. 3.   RNase protection of 1 µg of 10.5-day embryonic blood, 13.5-day fetal liver, and adult reticulocyte RNAs from strains beta sp/Agamma A and C (A) and from strains HS2 beta sp/Agamma B and C (B). Labeled RNA fragments corresponding to the beta sp/Agamma (exon 2 shown) and mouse alpha -globin (exon 2) genes were used as probes.

Cellulose acetate electrophoresis was performed to confirm the presence of both gamma -globin chains in 13.5-day fetal liver and adult erythrocytes. The fetal and adult erythrocytes of beta sp/Agamma and HS2 beta sp/Agamma transgenic mice contained endogenous mouse hemoglobins as well as an additional hemoglobin band composed of two mouse alpha -globin chains and two human gamma -globin chains (Fig. 4). These results were confirmed by acid-urea gel electrophoresis and high-pressure liquid chromatography (HPLC) analysis (data not shown).


View larger version (46K):
[in this window]
[in a new window]
 
FIG. 4.   Cellulose acetate electrophoresis of 14.5-day (A) and adult (B) peripheral blood lysates from strain beta sp/Agamma A. Positions of the endogenous mouse hemoglobins and the mouse alpha -2/human gamma -2 hemoglobin tetramer are shown. +, blood lysate from transgenic animal; -, blood lysate from littermate control.

Transgenic mice with cosmid gene constructs. A 37-kb µLCRAgamma psi beta delta beta cosmid construct (Fig. 5) containing a 4-kb µLCR linked to the Agamma -, psi beta -, delta -, and beta -globin genes was modified by replacing 381 bp of the Agamma -globin promoter with the 576-bp beta -spectrin promoter (Fig. 5). Three transgenic founder animals were generated with the resulting µLCRbeta spAgamma psi beta delta beta cosmid. High levels of beta sp/Agamma mRNA were detected in RNA from reticulocytes, bone marrow, and spleen, and no beta sp/Agamma mRNA was detected in RNA from thymus (Fig. 6). Southern blot analysis showed that these lines contained between 8 and 40 copies of the cosmid. One transgenic founder animal (strain C) did not transmit the transgene to F1 progeny and was concluded to be mosaic for the transgene. Transgene expression in this line was studied only in the founder animal. Three additional transgenic lines containing the control µLCRAgamma psi beta delta beta cosmid construct were generated for comparison.


View larger version (9K):
[in this window]
[in a new window]
 
FIG. 5.   Control and beta sp/Agamma cosmid constructs used to generate transgenic mice. The control µLCRAgamma psi beta delta beta cosmid originally described by Enver et al. (12) (A) was modified to replace the Agamma promoter region from -381 to -1 with a 576-bp fragment of the human beta -spectrin promoter (B). Transgenic mice were identified by Southern blot analysis using a 576-bp fragment containing the human beta -spectrin promoter region and a 960-bp fragment containing exon 2 of the human beta -globin gene as probes.


View larger version (38K):
[in this window]
[in a new window]
 
FIG. 6.   Analysis of beta sp/Agamma mRNA expression in transgenic mice containing the µLCRAgamma psi beta delta beta cosmid by RNase protection assay of 1 µg of bone marrow (BM) and spleen RNA and 10 µg of thymus RNA from strain µLCRbeta spAgamma psi beta delta beta A. Labeled RNA fragments corresponding to the beta sp/Agamma (exon 2 shown), mouse alpha -globin (exon 2), and mouse actin (control) genes were used as probes.

RNA was extracted from 10.5-dpc blood, 13.5-dpc fetal liver, and adult reticulocytes for RNase protection analysis of human gamma - and beta -globin mRNA levels during development. As described previously (12), we detected gamma -globin mRNA in yolk sac and fetal liver and beta -globin mRNA in fetal liver and adult erythroid cells of transgenic lines with the control µLCRAgamma psi beta delta beta cosmid (Fig. 7; Table 2). In contrast, both beta sp/Agamma mRNA and human beta -globin mRNA were detected at high levels in yolk sac, fetal liver, and adult erythroid cells of transgenic mice containing the µLCRbeta spAgamma psi beta delta beta cosmid (Fig. 7; Table 2).


View larger version (51K):
[in this window]
[in a new window]
 
FIG. 7.   RNase protection of 1 µg of 10.5-day embryonic blood, 13.5-day fetal liver, and adult reticulocyte RNA from control cosmid strain C (A) and from strain µLCRbeta spAgamma psi beta delta beta A (B). Labeled RNA fragments corresponding to the beta sp/Agamma (exon 2 shown), human beta -globin (exon 3), and mouse alpha -globin (exon 2) genes were used as probes.

                              
View this table:
[in this window]
[in a new window]
 
TABLE 2.   Expression of beta sp/Agamma mRNA in µLCRbeta spAgamma psi beta delta beta and µLCRAgamma psi beta delta beta transgenic mouse lines

Cellulose acetate electrophoresis was performed to confirm the presence of both gamma - and beta -globin chains in 13.5-day fetal liver and adult erythrocytes. Fetal erythrocytes from transgenic mice with either the control µLCRAgamma psi beta delta beta cosmid or the µLCRbeta spAgamma psi beta delta beta cosmid contained endogenous mouse hemoglobins as well as two additional hemoglobin bands consisting of two mouse alpha -globin and two human gamma -globin chains and two mouse alpha -globin and two human beta -globin chains (Fig. 8). Adult peripheral blood of control µLCRAgamma psi beta delta beta cosmid transgenic mice contained only the endogenous mouse hemoglobins and the mouse alpha -2/human beta -2 band. In contrast, adult erythrocytes of µLCRbeta spAgamma psi beta delta beta transgenic mice contained the endogenous mouse hemoglobins and both the mouse alpha -2/human gamma -2 and mouse alpha -2/human beta -2 bands (Fig. 8). These results were confirmed by HPLC analysis (data not shown).


View larger version (34K):
[in this window]
[in a new window]
 
FIG. 8.   Cellulose acetate electrophoresis of 14.5-day (14.5d) and adult peripheral blood lysates from control µLCRAgamma psi beta delta beta C (left) and µLCRbeta spAgamma psi beta delta beta A (right) transgenic mice. The positions of the endogenous mouse hemoglobins, the mouse alpha -2/human gamma -2 hemoglobin tetramer, and the mouse alpha -2/human beta -2 hemoglobin tetramer are shown. +, blood lysate from transgenic animal; -, blood lysate from littermate control.

Immunofluorescence analysis of 14.5-dpc fetal livers from µLCRbeta spAgamma psi beta delta beta embryos. Immunofluorescence analysis of human gamma - and beta -globin gene expression was done on 14.5-dpc fetal livers from µLCRbeta spAgamma psi beta delta beta transgenic embryos and control µLCRAgamma psi beta delta beta cosmid-containing embryos. As previously described, fetal liver cells from control µLCRAgamma psi beta delta beta cosmid-containing mice expressed either human beta -globin or human gamma -globin (12). Fetal liver cells from µLCRbeta spAgamma psi beta delta beta cosmid-containing mice all expressed both human gamma -globin and human beta -globin (Fig. 9).


View larger version (84K):
[in this window]
[in a new window]
 
FIG. 9.   Immunofluorescence analysis of beta sp/Agamma and human beta -globin chains in fetal liver cells from µLCRbeta spAgamma psi beta delta beta transgenic mice. The fetal liver cells were fixed and stained with conjugated monoclonal antibodies against human gamma -globin (FITC) and human beta -globin (rhodamine). The identical field was photographed with an FITC filter (gamma ), a rhodamine filter (beta ), and both filters (gamma +beta ).

    DISCUSSION
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

Analysis of transgenic mice containing either cosmids or yeast artificial chromosomes (YACs) has shown that appropriate developmental regulation requires the presence of an active globin gene or genes upstream of the beta -globin gene (4, 11, 12, 16, 17, 28, 37, 40, 43). However, these studies have not identified the specific sequences involved. Analysis of deletion constructs in transgenic mice or cultured cells demonstrated that deletion of the gamma -globin promoter allowed expression of the downstream beta -globin gene (3, 24). However, the same deletions which allow beta -globin gene expression abolished gamma -globin gene expression. Our data support the competition model for hemoglobin switching, which posits that the individual globin genes compete for stage-specific elements to stabilize transcription of individual globin genes. By replacing the gamma -globin promoter with the beta -spectrin promoter, the beta -globin gene is expressed at all stages of development in the presence of gamma -globin gene expression. We conclude that the sequences between -381 and +1 of the gamma -globin promoter, and not gamma -globin transcription or intragenic sequences, are necessary and sufficient to silence the downstream beta -globin gene in the embryonic stage of development.

The observation that the beta -spectrin promoter is an enhancer-dependent and erythroid cell-specific promoter makes it an ideal promoter for the studies described here. Previous analyses of transgenic mice carrying phosphoglycerate kinase-Neo gene constructs inserted into either the mouse beta -globin locus (49) or the mouse (13, 22) and human (5, 38) LCRs had strikingly negative effects on globin gene expression. It is clear from these studies that the phosphoglycerate kinase gene promoter or Neo sequences are not neutral substitutions and that they may be strong competitors for stage-specific elements and/or the LCR (41).

Our data also support models in which specific sequences in the gamma -globin promoter capture the LCR in the yolk sac erythroid cells and prevent beta -globin gene expression (2, 8, 24, 25). The testing of this model, and the importance of gene order and polarity, would require substitution of the beta -spectrin promoter for the Agamma -globin promoter in a YAC construct, which would place two globin promoters upstream of the beta -spectrin promoter. If the LCR specifically interacts with these promoters, we hypothesize that expression of the beta -globin gene will be suppressed in yolk sac erythroid cells.

Our data are not consistent with some aspects of the models in which stage-specific elements alone are responsible for hemoglobin switching (31). These models posit that the presence of an enhancer-dependent gamma -globin gene might be sufficient to suppress beta -globin expression in the yolk sac, in contrast to what we observed. The possibility that the beta -spectrin promoter does not compete with the beta -globin promoter for the same stage-specific factors which interact with the gamma -globin promoter can be tested in the YAC experiments as well.

Since the beta sp/Agamma globin gene is expressed at relatively high levels in erythroid cells at all stages of development, beta sp/Agamma transgenic mice may be useful to test the effects of gamma -globin on the amelioration of sickling in the sickle cell disease mouse model (35, 48). Previous in vitro studies have demonstrated that the amount of hemoglobin S (HbS) polymers decreases with increasing proportions of HbF, reaching a maximum inhibition of polymerization at 20% HbF (34). Other studies have found that as the HbF concentration increases, the severity of sickle cell disease decreases, with significantly less severe disease with >10% HbF (32, 36, 46). Generating sickle cell disease mice carrying the beta sp/Agamma gene would test whether the Agamma -globin expressed from the beta -spectrin promoter is sufficient to reduce HbS polymerization in the mouse model.

    ACKNOWLEDGMENTS

We thank Qiliang Li for providing the µLCRAgamma psi beta delta beta cosmid, Thalia Papayannopoulou and Betty Nakamoto for immunofluoresence analysis, and Griffin Rodgers for HPLC analysis. We also thank Nancy Seidel for providing K562 RNA and Theresa Hernandez for assistance in maintaining the mouse colony.

    FOOTNOTES

* Corresponding author. Mailing address: Hematopoiesis Section, Genetics and Molecular Biology Branch, National Human Genome Research Institute, National Institutes of Health, Building 49, Room 3A14 MSC 4442, Bethesda, MD 20892-4442. Phone: (301) 402-0902. Fax: (301) 402-4929. E-mail: tedyaz{at}nhgri.nih.gov.

    REFERENCES
Top
Abstract
Introduction
Materials & Methods
Results
Discussion
References

1. Alter, B. P., S. C. Goff, G. D. Efremov, M. E. Graveley, and T. H. J. Huisman. 1980. Globin chain electrophoresis: a new approach to the determination of the Ggamma /Agamma ratio in fetal haemoglobin and to studies of globin synthesis. Br. J. Haematol. 44:527-534[Medline].
2. Amrolia, P. J., L. Ramamurthy, D. Saluja, N. Tanese, S. M. Jane, and J. M. Cunningham. 1997. The activation domain of the enhancer binding protein p45NF-E2 interacts with TAFII130 and mediates long-range activation of the alpha - and beta -globin gene loci in an erythroid cell line. Proc. Natl. Acad. Sci. USA 94:10051-10056[Abstract/Free Full Text].
3. Anderson, K. P., J. A. Lloyd, E. Ponce, S. C. Crable, J. C. Neumann, and J. B. Lingrel. 1993. Regulated expression of the human beta -globin gene in transgenic mice requires an upstream globin or nonglobin promoter. Mol. Biol. Cell 4:1077-1085[Abstract].
4. Behringer, R. R., T. M. Ryan, R. D. Palmiter, R. L. Brinster, and T. M. Townes. 1990. Human gamma  to beta -globin gene switching in transgenic mice. Genes Dev. 4:380-389[Abstract/Free Full Text].
5. Bungert, J., U. Dave, K.-C. Lim, K. H. Lieuw, J. A. Shavit, Q. Liu, and J. D. Engel. 1995. Synergistic regulation of human beta -globin switching by locus control region elements HS3 and HS4. Genes Dev. 9:3083-3096[Abstract/Free Full Text].
6. Caterina, J. J., T. M. Ryan, K. M. Pawlik, R. D. Palmiter, R. L. Brinster, R. R. Behringer, and T. M. Townes. 1991. Human beta -globin locus control region: analysis of the 5' DNase I hypersensitive site HS2 in transgenic mice. Proc. Natl. Acad. Sci. USA 88:1626-1630[Abstract/Free Full Text].
7. Chada, K., J. Magram, and F. Costantini. 1986. An embryonic pattern of expression of a human fetal globin gene in transgenic mice. Nature 319:685-689[Medline].
8. Choi, O., and J. Engel. 1988. Developmental regulation of beta -globin gene switching. Cell 55:17-26[Medline].
9. Collins, F. S., and S. M. Weissman. 1984. The molecular genetics of human hemoglobin. Prog. Nucleic Acid Res. Mol. Biol. 31:315-462[Medline].
10. Dillon, N., J. Strouboulis, and F. Grosveld. 1995. The regulation of human beta -globin gene expression: polarity of transcriptional competition in the human beta -globin locus, p. 23-28. In G. Stamatoyannopoulos (ed.), Molecular biology of hemoglobin switching. Intercept Ltd., Andover, England.
11. Enver, T., A. J. Ebens, W. C. Forrester, and G. Stamatoyannopoulos. 1989. The human beta -globin locus activation region alters the developmental fate of a human fetal globin gene in transgenic mice. Proc. Natl. Acad. Sci. USA 86:7033-7037[Abstract/Free Full Text].
12. Enver, T., N. Raich, A. J. Ebens, T. Papayannopoulou, F. Costantini, and G. Stamatoyannopoulos. 1990. Developmental regulation of human fetal-to-adult globin gene switching in transgenic mice. Nature 344:309-313[Medline].
13. Fiering, S., E. Epner, K. Robinson, Y. Zhuang, A. Telling, M. Hu, D. I. K. Martin, T. Enver, T. J. Ley, and M. Groudine. 1995. Targeted deletion of 5'HS2 of the murine beta -globin LCR reveals that it is not essential for proper regulation of the beta -globin locus. Genes Dev. 9:2203-2213[Abstract/Free Full Text].
14. Forrester, W. C., U. Novak, R. Gelinas, and M. Groudine. 1989. Molecular analysis of the human beta -globin locus activation region. Proc. Natl. Acad. Sci. USA 86:5439-5443[Abstract/Free Full Text].
15. Fraser, P., J. Hurst, P. Collis, and F. Grosveld. 1990. DNase I hypersensitive sites 1, 2 and 3 of the human beta -globin dominant control region direct position-independent expression. Nucleic Acids Res. 18:3503-3508[Abstract/Free Full Text].
16. Furukawa, T., P. A. Navas, B. M. Josephson, K. R. Peterson, T. Papayannopoulou, and G. Stamatoyannopoulos. 1995. Coexpression of varepsilon , Ggamma and Agamma globin mRNA in embryonic red blood cells from a single copy beta -YAC transgenic mouse. Blood Cells Mol. Dis. 21:168-178[Medline].
17. Gaensler, K. M., M. Kitamura, and Y. W. Kan. 1993. Germ-line transmission and developmental regulation of a 150-kb yeast artificial chromosome containing the human beta -globin locus in transgenic mice. Proc. Natl. Acad. Sci. USA 90:11381-11385[Abstract/Free Full Text].
18. Gallagher, P. G., D. E. Sabatino, M. Romana, A. P. Cline, L. J. Garrett, D. M. Bodine, and B. G. Forget. A human beta -spectrin gene promoter directs high level expression in erythroid, but not muscle or neural cells. Submitted for publication.
19. Grosveld, F., G. B. van Assendelft, D. R. Greaves, and G. Kollias. 1987. Position-independent, high-level expression of the human beta -globin gene in transgenic mice. Cell 51:975-985[Medline].
20. Hanscombe, O., D. Whyatt, P. Fraser, N. Yannoutsos, D. Greaves, N. Dillon, and F. Grosveld. 1991. Importance of globin gene order for correct developmental expression. Genes Dev. 5:1387-1394[Abstract/Free Full Text].
21. Hogan, B., F. Costantini, and E. Lacy. 1986. Manipulating the mouse embryo. A laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
22. Hug, B. A., R. L. Wesselschmidt, S. Fiering, M. A. Bender, E. Epner, M. Groudine, and T. J. Ley. 1996. Analysis of mice containing a targeted deletion of the murine beta -globin locus control region 5' hypersensitive site 3. Mol. Cell. Biol. 16:2906-2912[Abstract/Free Full Text].
23. Jane, S. M., and J. M. Cunningham. 1996. Molecular mechanisms of hemoglobin switching. Int. J. Biochem. Cell Biol. 28:1197-1209[Medline].
24. Jane, S. M., P. A. Ney, E. F. Vanin, D. L. Gumucio, and A. W. Nienhuis. 1992. Identification of a stage selector element in the human gamma-globin gene promoter that fosters preferential interaction with the 5' HS2 enhancer when in competition with the beta-promoter. EMBO J. 11:2961-2969[Medline].
25. Jane, S. M., A. W. Nienhuis, and J. M. Cunningham. 1995. Hemoglobin switching in man and chicken is mediated by a heteromeric complex between the ubiquitous transcription factor CP2 and a developmentally specific protein. EMBO J. 14:97-105[Medline]. (Erratum, 14:854.)
26. Kollias, G., N. Wrighton, J. Hurst, and F. Grosveld. 1986. Regulated expression of human Agamma -, beta - and hybrid gamma beta -globin genes in transgenic mice: manipulation of developmental expression patterns. Cell 46:89-94[Medline].
27. Liu, D., J. C. Chang, P. Moi, W. Jiu, Y. W. Kan, and P. T. Curtin. 1992. Dissection of the enhancer activity of beta -globin 5' DNase I-hypersensitive site 2 in transgenic mice. Proc. Natl. Acad. Sci. USA 89:3899-3903[Abstract/Free Full Text].
28. Liu, Q., J. Bungert, and J. Engel. 1997. Mutation of gene-proximal regulatory elements disrupts human varepsilon -, gamma -, and beta -globin expression in yeast artificial chromosome transgenic mice. Proc. Natl. Acad. Sci. USA 94:169-174[Abstract/Free Full Text].
29. Magram, J., K. Chada, and F. Costantini. 1985. Developmental regulation of a cloned adult beta -globin gene in transgenic mice. Nature 315:338-340[Medline].
30. Maniatis, T., E. F. Fritsch, and J. Sambrook. 1982. Molecular cloning: a laboratory manual. Cold Spring Harbor Laboratory, Cold Spring Harbor, N.Y.
31. Martin, D. I., S. Fiering, and M. Groudine. 1996. Regulation of beta -globin gene expression: straightening out the locus. Curr. Opin. Genet. Dev. 6:488-495[Medline].
32. Miller, B. A., M. Salameh, M. Ahmed, N. Olivieri, T. Huisman, S. Orkin, and D. Nathan. 1987. Analysis of high fetal hemoglobin production in sickle cell anemia patients from the eastern province of Saudi Arabia, p. 415-426. In G. Stamatoyannopoulos, and A. Nienhuis (ed.), Developmental control of globin gene expression. Alan R. Liss, Inc., New York, N.Y.
33. Ney, P. A., B. P. Sorrentino, K. T. McDonagh, and A. W. Nienhuis. 1990. Tandem AP-1-binding sites within the human beta -globin dominant control region function as an inducible enhancer in erythroid cells. Genes Dev. 4:993-1006[Abstract/Free Full Text].
34. Noguchi, C. T., G. P. Rodgers, G. Serjeant, and A. N. Schechter. 1988. Levels of fetal hemoglobin necessary for treatment of sickle cell disease. N. Engl. J. Med. 318:96-99[Medline].
35. Paszty, C., C. M. Brion, E. Manci, H. E. Witkowska, M. E. Stevens, N. Mohandas, and E. M. Rubin. 1997. Transgenic knockout mice with exclusively human sickle hemoglobin and sickle cell disease. Science 278:876-878[Abstract/Free Full Text].
36. Perrine, R. P., M. J. Brown, J. B. Clegg, D. J. Weatherall, and A. May. 1972. Benign sickle cell anaemia. Lancet ii:1163-1167.
37. Peterson, K. R., C. H. Clegg, C. Huxley, B. M. Josephson, H. S. Haugen, T. Furukawa, and G. Stamatoyannopoulos. 1993. Transgenic mice containing a 248-kb yeast artificial chromosome carrying the human beta -globin locus display proper developmental control of human globin genes. Proc. Natl. Acad. Sci. USA 90:7593-7597[Abstract/Free Full Text].
38. Peterson, K. R., C. H. Clegg, P. A. Navas, E. J. Norton, T. G. Kimbrough, and G. Stamatoyannopoulos. 1996. Effect of deletion of 5'HS3 or 5'HS2 of the human beta -globin locus control region on the developmental regulation of globin gene expression in beta -globin locus yeast artificial chromosome transgenic mice. Proc. Natl. Acad. Sci. USA 93:6605-6609[Abstract/Free Full Text].
39. Peterson, K. R., and G. Stamatoyannopoulos. 1993. Role of gene order in developmental control of human gamma - and beta -globin gene expression. Mol. Cell. Biol. 13:4836-4843[Abstract/Free Full Text].
40. Peterson, K. R., Q. L. Li, C. H. Clegg, T. Furukawa, P. A. Navas, E. J. Norton, T. C. Kimbrough, and G. Stamatoyannopoulos. 1995. Use of yeast artificial chromosomes (YACs) in studies of mammalian development: production of beta -globin locus YAC mice carrying human globin developmental mutants. Proc. Natl. Acad. Sci. USA 92:5655-5659[Abstract/Free Full Text].
41. Pham, C. T. N., D. M. MacIvor, B. A. Hug, J. W. Heusel, and T. J. Ley. 1996. Long range disruption of gene expression by a selectable marker cassette. Proc. Natl. Acad. Sci. USA 93:13090-13095[Abstract/Free Full Text].
42. Philipsen, S., D. Talbot, P. Fraser, and F. Grosveld. 1990. The beta -globin dominant control region: hypersensitive site 2. EMBO J. 9:2159-2167[Medline].
43. Porcu, S., M. Kitamura, E. Witkowska, Z. Zhang, A. Mutero, C. Lin, J. Chang, and K. M. Gaensler. 1997. The human beta -globin locus introduced by YAC transfer exhibits a specific and reproducible pattern of developmental regulation in transgenic mice. Blood 90:4602-4609[Abstract/Free Full Text].
44. Prchal, J. T., T. Papayannopoulou, and S. Yoon. 1990. Patterns of spectrin transcripts in erythroid and non-erythroid cells. J. Cell. Physiol. 144:287-294[Medline].
45. Raich, N., T. Enver, B. Nakamoto, B. Josephson, T. Papayannopoulou, and G. Stamatoyannopoulos. 1990. Autonomous developmental control of human embryonic globin gene switching in transgenic mice. Science 250:1147-1149[Abstract/Free Full Text].
46. Rucknagel, D. L., S. A. Sarniak, C. F. Whitten, and D. A. Odenheimer. 1987. Fetal hemoglobin concentration predicts disease severity in children with sickle cell anemia, p. 487-496. In G. Stamatoyannopoulos, and A. Nienhuis (ed.), Developmental control of globin gene expression. Alan R. Liss, Inc., New York, N.Y.
47. Ryan, T. M., R. R. Behringer, N. C. Martin, T. M. Townes, R. D. Palmiter, and R. L. Brinster. 1989. A single erythroid-specific DNase I super-hypersensitive site activates high levels of human beta -globin gene expression in transgenic mice. Genes Dev. 3:314-323[Abstract/Free Full Text].
48. Ryan, T. M., D. J. Ciavatta, and T. M. Townes. 1997. Knockout-transgenic mouse model of sickle cell disease. Science 278:873-875[Abstract/Free Full Text].
49. Shehee, W. R., P. Oliver, and O. Smithies. 1993. Lethal thalassemia after insertional disruption of the mouse major adult beta-globin gene. Proc. Natl. Acad. Sci. USA 90:3177-3181[Abstract/Free Full Text].
50. Sorrentino, B., P. Ney, D. Bodine, and A. W. Nienhuis. 1990. A 46 base pair enhancer sequence within the locus activation region is required for induced expression of the gamma -globin gene during erythroid differentiation. Nucleic Acids Res. 18:2721-2731[Abstract/Free Full Text].
51. Stamatoyannopoulos, G., and A. W. Nienhuis. 1993. Hemoglobin switching, p. 107-156. In G. Stamatoyannopoulos, A. W. Nienhuis, and H. Varmus (ed.), Molecular basis of blood diseases. Saunders, Philadelphia, Pa.
52. Starck, J., R. Sarker, M. Romana, A. Bhargava, A. L. Scarpa, M. Tanaka, J. W. Chamberlain, S. M. Weissman, and B. G. Forget. 1994. Developmental regulation of human gamma - and beta -globin genes in the absence of the locus control region. Blood 84:1656-1665[Abstract/Free Full Text].
53. Townes, T. M., J. B. Lingrel, H. Y. Chen, R. L. Brinster, and R. D. Palmiter. 1985. Erythroid-specific expression of human beta -globin genes in transgenic mice. EMBO J. 4:1715-1723[Medline].
54. Tuan, D., W. Solomon, I. London, and D. Lee. 1989. An erythroid-specific, developmental-stage-independent enhancer far upstream of the human `beta -like globin' genes. Proc. Natl. Acad. Sci. USA 86:2554-2558[Abstract/Free Full Text].
55. Whitney, J. B., III. 1978. Simplified typing of mouse hemoglobin (Hbb) phenotypes using cystamine. Biochem. Genet. 16:667-672[Medline].
56. Wijgerde, M., F. Grosveld, and P. Fraser. 1995. Transcription complex stability and chromatin dynamics in vivo. Nature 377:209-213[Medline].
57. Winkelmann, J. C., and B. G. Forget. 1993. Erythroid and nonerythroid spectrins. Blood 81:3173-3185[Abstract/Free Full Text].
58. Wood, W. G., J. B. Clegg, and D. J. Weatherall. 1977. Developmental biology of human hemoglobins. Prog. Hematol. 10:43-90[Medline].


Molecular and Cellular Biology, November 1998, p. 6634-6640, Vol. 18, No. 11
0270-7306/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.



This article has been cited by other articles:

  • Beauchemin, H., Trudel, M. (2009). Evidence for a Bigenic Chromatin Subdomain in Regulation of the Fetal-to-Adult Hemoglobin Switch. Mol. Cell. Biol. 29: 1635-1648 [Abstract] [Full Text]  
  • Kanno, H., Utsugisawa, T., Aizawa, S., Koizumi, T., Aisaki, K.-i., Hamada, T., Ogura, H., Fujii, H. (2007). Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency. haematol 92: 731-737 [Abstract] [Full Text]  
  • Yu, M., Han, H., Xiang, P., Li, Q., Stamatoyannopoulos, G. (2006). Autonomous Silencing as Well as Competition Controls {gamma}-Globin Gene Expression during Development. Mol. Cell. Biol. 26: 4775-4781 [Abstract] [Full Text]  
  • Gallagher, P. G., Nilson, D. G., Wong, C., Weisbein, J. L., Garrett-Beal, L. J., Eber, S. W., Bodine, D. M. (2005). A dinucleotide deletion in the ankyrin promoter alters gene expression, transcription initiation and TFIID complex formation in hereditary spherocytosis. Hum Mol Genet 14: 2501-2509 [Abstract] [Full Text]  
  • Calderwood, M. S., Gannoun-Zaki, L., Wellems, T. E., Deitsch, K. W. (2003). Plasmodium falciparum var Genes Are Regulated by Two Regions with Separate Promoters, One Upstream of the Coding Region and a Second within the Intron. J. Biol. Chem. 278: 34125-34132 [Abstract] [Full Text]  
  • Frazar, T. F., Weisbein, J. L., Anderson, S. M., Cline, A. P., Garrett, L. J., Felsenfeld, G., Gallagher, P. G., Bodine, D. M. (2003). Variegated Expression from the Murine Band 3 (AE1) Promoter in Transgenic Mice Is Associated with mRNA Transcript Initiation at Upstream Start Sites and Can Be Suppressed by the Addition of the Chicken {beta}-Globin 5' HS4 Insulator Element. Mol. Cell. Biol. 23: 4753-4763 [Abstract] [Full Text]  
  • Persons, D. A., Hargrove, P. W., Allay, E. R., Hanawa, H., Nienhuis, A. W. (2003). The degree of phenotypic correction of murine beta -thalassemia intermedia following lentiviral-mediated transfer of a human gamma -globin gene is influenced by chromosomal position effects and vector copy number. Blood 101: 2175-2183 [Abstract] [Full Text]  
  • Boulanger, L., Sabatino, D. E., Wong, E. Y., Cline, A. P., Garrett, L. J., Garbarz, M., Dhermy, D., Bodine, D. M., Gallagher, P. G. (2002). Erythroid Expression of the Human alpha -Spectrin Gene Promoter Is Mediated by GATA-1- and NF-E2-binding Proteins. J. Biol. Chem. 277: 41563-41570 [Abstract] [Full Text]  
  • Gallagher, P. G., Sabatino, D. E., Basseres, D. S., Nilson, D. M., Wong, C., Cline, A. P., Garrett, L. J., Bodine, D. M. (2001). Erythrocyte Ankyrin Promoter Mutations Associated with Recessive Hereditary Spherocytosis Cause Significant Abnormalities in Ankyrin Expression. J. Biol. Chem. 276: 41683-41689 [Abstract] [Full Text]  
  • Sargent, T. G., Lloyd, J. A. (2001). The Human gamma -Globin TATA and CACCC Elements Have Key, Distinct Roles in Suppressing beta -Globin Gene Expression in Embryonic/Fetal Development. J. Biol. Chem. 276: 41817-41824 [Abstract] [Full Text]  
  • Moreau-Gaudry, F., Xia, P., Jiang, G., Perelman, N. P., Bauer, G., Ellis, J., Surinya, K. H., Mavilio, F., Shen, C.-K., Malik, P. (2001). High-level erythroid-specific gene expression in primary human and murine hematopoietic cells with self-inactivating lentiviral vectors. Blood 98: 2664-2672 [Abstract] [Full Text]  
  • Persons, D. A., Allay, E. R., Sabatino, D. E., Kelly, P., Bodine, D. M., Nienhuis, A. W. (2001). Functional requirements for phenotypic correction of murine {beta}-thalassemia: implications for human gene therapy. Blood 97: 3275-3282 [Abstract] [Full Text]  
  • Sabatino, D. E., Seidel, N. E., Aviles-Mendoza, G. J., Cline, A. P., Anderson, S. M., Gallagher, P. G., Bodine, D. M. (2000). Long-term expression of gamma -globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma -globin gene fused to the ankyrin-1 promoter. Proc. Natl. Acad. Sci. USA 10.1073/pnas.230453097v1 [Abstract] [Full Text]  
  • Zhou, W., Clouston, D. R., Wang, X., Cerruti, L., Cunningham, J. M., Jane, S. M. (2000). Induction of Human Fetal Globin Gene Expression by a Novel Erythroid Factor, NF-E4. Mol. Cell. Biol. 20: 7662-7672 [Abstract] [Full Text]  
  • Ryan, T. M., Sun, C.-W., Ren, J., Townes, T. M. (2000). Human {gamma}-globin gene promoter element regulates human {beta}-globin gene developmental specificity. Nucleic Acids Res 28: 2736-2740 [Abstract] [Full Text]  
  • Sargent, T. G., DuBois, C. C., Buller, A. M., Lloyd, J. A. (1999). The Roles of 5'-HS2, 5'-HS3, and the gamma -Globin TATA, CACCC, and Stage Selector Elements in Suppression of beta -Globin Expression in Early Development. J. Biol. Chem. 274: 11229-11236 [Abstract] [Full Text]  
  • Gallagher, P. G., Sabatino, D. E., Romana, M., Cline, A. P., Garrett, L. J., Bodine, D. M., Forget, B. G. (1999). A Human beta -Spectrin Gene Promoter Directs High Level Expression in Erythroid but Not Muscle or Neural Cells. J. Biol. Chem. 274: 6062-6073 [Abstract] [Full Text]  
  • Sabatino, D. E., Wong, C., Cline, A. P., Pyle, L., Garrett, L. J., Gallagher, P. G., Bodine, D. M. (2000). A Minimal Ankyrin Promoter Linked to a Human gamma -Globin Gene Demonstrates Erythroid Specific Copy Number Dependent Expression with Minimal Position or Enhancer Dependence in Transgenic Mice. J. Biol. Chem. 275: 28549-28554 [Abstract] [Full Text]  
  • Sabatino, D. E., Seidel, N. E., Aviles-Mendoza, G. J., Cline, A. P., Anderson, S. M., Gallagher, P. G., Bodine, D. M. (2000). Long-term expression of gamma -globin mRNA in mouse erythrocytes from retrovirus vectors containing the human gamma -globin gene fused to the ankyrin-1 promoter. Proc. Natl. Acad. Sci. USA 97: 13294-13299 [Abstract] [Full Text]  

This Article
Right arrow Abstract Freely available
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow E-mail this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrowReprints and Permissions
Right arrow Copyright Information
Right arrow Books from ASM Press
Right arrow MicrobeWorld
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Sabatino, D. E.
Right arrow Articles by Bodine, D. M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Sabatino, D. E.
Right arrow Articles by Bodine, D. M.